TOPLINE Dupilumab reduced severe exacerbations of asthma, levels of total serum immunoglobulin E (IgE), and improved lung function and asthma control in children with uncontrolled moderate-to-severe type 2 asthma with monoallergen or multiallergen sensitization. METHODOLOGY Researchers conducted a post hoc analysis of the VOYAGE trial to assess whether dupilumab was effective in children aged 6-11 …
Read More
Dupilumab Reduces Exacerbations in Kids With Type 2 Asthma
